On the other hand, a growing evidence supports the notion that HER2 inhibitors are a potential treatment for diabetes [9, 41], obesity [37], and kidney disease [10, 42]. This evidence concerns the gene ERBB2 and obesity due to melanocortin 4 receptor deficiency.